Skip to Content

IntelliPharmaCeutics International Inc IPCIF

Morningstar Rating
$0.06 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IPCIF is trading at a 363% premium.
Price
$0.06
Fair Value
$5.39
Uncertainty
Extreme
1-Star Price
$2.38
5-Star Price
$9.24
Economic Moat
Sqr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPCIF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.06
Day Range
$0.060.06
52-Week Range
$0.010.14
Bid/Ask
$0.04 / $0.10
Market Cap
$1.99 Mil
Volume/Avg
12,826 / 8,083

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.44
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
11

Valuation

Metric
IPCIF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
2.44
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IPCIF
Quick Ratio
0.05
Current Ratio
0.06
Interest Coverage
−8.88
Quick Ratio
IPCIF

Profitability

Metric
IPCIF
Return on Assets (Normalized)
−127.79%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
IPCIF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBhmhskgyjMyg$605.7 Bil
VRTX
Vertex Pharmaceuticals IncVwbygcqmhPcndtqw$116.3 Bil
REGN
Regeneron Pharmaceuticals IncVwynqbmbjPdlthjv$108.0 Bil
MRNA
Moderna IncBntvsxsdgSbxnn$62.9 Bil
BNTX
BioNTech SE ADRQzszdmzMymh$23.9 Bil
ARGX
argenx SE ADRCxcvncyxMllk$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncKgxhxgrjKtxqkb$18.9 Bil
BMRN
Biomarin Pharmaceutical IncPvmkdckjPpzbhl$14.5 Bil
INCY
Incyte CorpHgrjrrxhQjhhz$12.9 Bil
RPRX
Royalty Pharma PLC Class AKfqxdwtprZlftw$12.3 Bil

Sponsor Center